{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:07:27Z","timestamp":1768709247962,"version":"3.49.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019092","name":"Natural Science Foundation for Distinguished Young Scholars of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study is aim to evaluate the cost-effectiveness of Nivolumab plus ipilimumab vs. platinum plus chemotherapy for the first-line treatment of unresectable MPM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Markov model was developed to compare the cost and quality-adjusted life-year (QALY) of nivolumab plus ipilimumab and chemotherapy over a 10-year time horizon. Clinical efficacy and safety data were extracted from the CheckMate 743 trials. Health state utilities were obtained from published literature. Costs were collected from an US payer perspective. One-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the cost-effectiveness's results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the base case analysis, the incremental healthcare costs and QALYs for Nivolumab plus Ipilimumab vs. chemotherapy are $196,604.22 and 0.53, respectively, resulting an incremental cost-effectiveness ratio (ICER) of $372,414.28\/QALYs for the model cohort of patients with locally advanced or metastatic MPM. However, Probabilistic sensitivity analysis showed that there was no probability that Nivolumab plus ipilimumab was cost-effective within the fluctuation range of other model parameters in first-line in unresectable MPM. The results of one-way sensitivity analysis showed that the cost of Nivolumab was the most sensitive parameter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The ICER of Nivolumab plus ipilimumab is above the theoretical willingness-to-pay threshold in the U.S, which suggests that first-line nivolumab plus ipilimumab for unresectable MPM may be not a cost-effective choice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.947375","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T12:00:43Z","timestamp":1658491243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhuo-miao","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Qing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging treatments for malignant pleural mesothelioma: where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1758835920971421","DOI":"10.1177\/1758835920971421","article-title":"Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma","volume":"12","author":"Yang","year":"2020","journal-title":"Ther Adv Med Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/17476348.2019.1679119","article-title":"Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma","volume":"13","author":"Kuribayashi","year":"2019","journal-title":"Expert Rev Respir Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e000669","DOI":"10.1136\/esmoopen-2019-000669","article-title":"How I treat malignant pleural mesothelioma","volume":"4","author":"Viscardi","year":"2020","journal-title":"ESMO Open."},{"key":"B6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/cancers13112793","article-title":"Immunotherapeutic approaches in malignant pleural mesothelioma","volume":"13","author":"Terenziani","year":"2021","journal-title":"Cancers."},{"key":"B8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/jcm10112290","article-title":"Oncological frontiers in the treatment of malignant pleural mesothelioma","volume":"10","author":"Vita","year":"2021","journal-title":"J Clin Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in malignant pleural mesothelioma","volume":"10","author":"de Gooijer","year":"2020","journal-title":"Front Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.2147\/OTT.S317434","article-title":"Advances in immunotherapy of malignant pleural mesothelioma","volume":"14","author":"Liao","year":"2021","journal-title":"Onco Targets Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1111\/j.1469-0691.2010.03331.x","article-title":"Understanding cost-effectiveness","volume":"16","author":"Zilberberg","year":"2010","journal-title":"Clin Microbiol Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jval.2016.04.011","article-title":"Accounting for cured patients in cost-effectiveness analysis","volume":"20","author":"Othus","year":"2017","journal-title":"Value Health."},{"key":"B14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jval.2018.10.007","article-title":"Survival extrapolation in cancer immunotherapy: a validation-based case study","volume":"22","author":"Bullement","year":"2019","journal-title":"Value Health."},{"key":"B15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/978-1-59745-416-2_24","article-title":"Epidemiology of lung cancer prognosis: quantity and quality of life","volume":"471","author":"Yang","year":"2009","journal-title":"Methods Mol Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40273-017-0527-z","article-title":"Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States Pharmacoeconomics","volume":"35","author":"Huang","year":"2017"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s11096-020-01076-3","article-title":"Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer","volume":"42","author":"Lin","year":"2020","journal-title":"Int J Clin Pharm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-effectiveness thresholds: the past, the present and the future","volume":"36","author":"Thokala","year":"2018","journal-title":"Pharmacoeconomics."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9195","DOI":"10.2147\/CMAR.S223441","article-title":"Cost-effectiveness analysis of ceritinib and alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer","volume":"11","author":"Liu","year":"2019","journal-title":"Cancer Manag Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2217\/cer-2020-0053","article-title":"Cost-effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer","volume":"9","author":"Zhang","year":"2020","journal-title":"J Comp Eff Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/1759-7714.12153","article-title":"Mouse double minute-2 homolog (MDM2)-rs2279744 polymorphism associated with lung cancer risk in a Northeastern Chinese population","volume":"6","author":"Wang","year":"2015","journal-title":"Thorac Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.05.012","article-title":"Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial","volume":"110","author":"Zhan","year":"2017","journal-title":"Lung Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o","article-title":"Development of WHO guidelines on generalized cost-effectiveness analysis","volume":"9","author":"Murray","year":"2000","journal-title":"Health Econ."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.21037\/atm-21-1803","article-title":"Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China","volume":"9","author":"Yang","year":"2021","journal-title":"Ann Transl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/bjs.9501","article-title":"Cost-effectiveness of early laparoscopic cholecystectomy for mild acute gallstone pancreatitis","volume":"101","author":"Morris","year":"2014","journal-title":"Br J Surg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1002\/ONCO.13522","article-title":"Cost-effectiveness of pembrolizumab plus axitinib versus sunitinib as first-line therapy in advanced renal cell carcinoma in the US","volume":"26","author":"Ding","year":"2021","journal-title":"Oncologist."},{"key":"B29","first-page":"3779coe","article-title":"Cost effectiveness of avelumab for metastatic merkel cell carcinoma","volume-title":"Pharmacoecon Open.","author":"Bullement","year":"2019"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2217\/fon-2019-0821","article-title":"Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma","volume":"16","author":"Zhang","year":"2020","journal-title":"Future Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1097\/CM9.0000000000000536","article-title":"First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China","volume":"132","author":"Li","year":"2019","journal-title":"Chin Med J."},{"key":"B32","unstructured":"2022"},{"key":"B33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/13696998.2020.1715414","article-title":"Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States","volume":"23","author":"Haddad","year":"2020","journal-title":"J Med Econ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.oraloncology.2017.09.017","article-title":"Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer","volume":"74","author":"Ward","year":"2017","journal-title":"Oral Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1078-0432.CCR-21-1466","article-title":"FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21443","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcomes."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e218787","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B39","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0140-6736(21)00147-1","article-title":"Immune checkpoint inhibitors in mesothelioma: a turning point","volume":"397","author":"Ceresoli","year":"2021","journal-title":"Lancet."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.947375\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T12:00:46Z","timestamp":1658491246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.947375\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":39,"alternative-id":["10.3389\/fpubh.2022.947375"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.947375","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"article-number":"947375"}}